Introduction Neo/adjuvant therapy for early-stage breast cancer has become increasingly
common in the last few decades; as a consequence, the number of breast cancer survivors …

Historically, metastatic melanoma was considered a highly lethal disease. However, recent
advances in drug development have allowed a significative improvement in prognosis. In …

Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop
brain metastases (BMs) during their disease, with considerable morbidity and mortality. The …

Simple Summary Immunotherapy has revolutionized the therapeutic landscape of
melanoma. However, the absence of clinically validated predictive biomarkers is one of the …

Background Endocrine therapy (ET) plus cyclin-dependent-kinases 4/6 inhibitors (CDK4/6i)
represents the standard treatment for luminal-metastatic breast cancer (MBC). However …

Background Body composition, has been established as a risk factor for colorectal cancer
diagnosis and disease progression. Aim of this study was to investigate the prognostic role …

Background Endocrine therapy (ET) is the mainstay of treatment for hormone receptor-
positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast …

Patients with melanoma brain metastases (MBM) have poor prognosis, albeit advances in
locoregional and systemic treatments. The melanoma-specific Graded Prognostic …

Background The optimal strategy for second-line (IIL) treatment in KRAS wt metastatic
colorectal cancer (mCRC) is not determined yet. Methods A random-effect NMA of phase II/III …

Despite surgical resection and adjuvant therapies, stage III melanomas still have a
substantial risk of relapse. Neoadjuvant therapy is an emerging strategy that might offer …